Impact of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management

Abstract

The objective of this study was to assess the impact of ⁶⁸Ga-prostate-specific membrane antigen (⁶⁸Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). <b>Methods:</b> Documented management plans before and after ⁶⁸Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. <b>Results:</b> Management changed after ⁶⁸Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (<i>P</i> &lt; 0.001) and higher prostate-specific antigen (PSA) levels (<i>P</i> = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. <b>Conclusion:</b>⁶⁸Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive ⁶⁸Ga-PSMA scan results, and higher PSA levels.